Drugs / fluzopanib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05551208 | Aug 2022 → Aug 2024 overdue | ovarian cancer | Chongqing University Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluzopanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05551208 ↗ |